FDA CDER Guidance on AI in Manufacturing Puts SMBs at Risk
CDER’s quiet rulemaking will force AI vendors in pharma from flashy demos to auditable, validated systems. Expect procurement, liability, and pricing to pivot. Startups may be squeezed while cloud giants standardize compliance. Read how validation artifacts, immutable logs, and lifecycle monitoring will decide which AI firms survive and profit now.
